Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
505
Stocks News & Analysis
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
stocks
WOW earnings: Woolworths losing market share, but will catch up to Coles
Woolworths have had a soft start to a challenging year, but Morningstar analyst believes it will eventually catch up to its main competitor.
stocks
Chart of the Week: Largest share price falls during earnings
Opportunities arise when the market overreacts, and good quality companies are mispriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,241.10 | 0.50 | -0.01% |
| CAC 40 | 7,773.88 | 29.95 | 0.39% |
| DAX 40 | 24,048.84 | 2.63 | 0.01% |
| Dow JONES (US) | 45,565.23 | 147.16 | 0.32% |
| FTSE 100 | 9,228.56 | 26.94 | -0.29% |
| HKSE | 24,998.82 | 202.94 | -0.81% |
| NASDAQ | 21,590.14 | 45.87 | 0.21% |
| Nikkei 225 | 42,828.79 | 308.52 | 0.73% |
| NZX 50 Index | 12,903.08 | 41.24 | 0.32% |
| S&P 500 | 6,481.40 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,980.00 | 9.50 | 0.11% |
| SSE Composite Index | 3,843.60 | 43.25 | 1.14% |